• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Friday's Pre-Market Session

    5/3/24 8:06:34 AM ET
    $AEON
    $ARDX
    $ATHE
    $BFRG
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AEON alert in real time by email

    Gainers

    • Helius Medical Tech (NASDAQ:HSDT) shares increased by 48.9% to $3.96 during Friday's pre-market session. The company's market cap stands at $3.5 million.
    • Vaxxinity (NASDAQ:VAXX) shares moved upwards by 41.17% to $0.15. The company's market cap stands at $18.6 million.
    • Jaguar Health (NASDAQ:JAGX) shares moved upwards by 28.37% to $0.38. The market value of their outstanding shares is at $108.1 million.
    • Healthcare Triangle (NASDAQ:HCTI) shares moved upwards by 19.56% to $1.47. The company's market cap stands at $6.8 million.
    • Ardelyx (NASDAQ:ARDX) stock increased by 16.64% to $7.92. The company's market cap stands at $1.8 billion. As per the news, the Q1 earnings report came out yesterday.
    • Owens & Minor (NYSE:OMI) stock increased by 13.99% to $27.94. The company's market cap stands at $2.1 billion. As per the press release, Q1 earnings came out today.

    Losers

    • AEON Biopharma (AMEX:AEON) stock declined by 44.4% to $1.87 during Friday's pre-market session. The company's market cap stands at $71.2 million.
    • Bullfrog AI Hldgs (NASDAQ:BFRG) stock decreased by 13.19% to $2.7. The company's market cap stands at $21.1 million.
    • Cardiff Oncology (NASDAQ:CRDF) stock declined by 11.17% to $3.98. The company's market cap stands at $177.9 million. As per the news, the Q1 earnings report came out yesterday.
    • Alterity Therapeutics (NASDAQ:ATHE) shares declined by 9.35% to $1.94. The market value of their outstanding shares is at $16.9 million.
    • NanoVibronix (NASDAQ:NAOV) shares decreased by 9.19% to $0.67. The company's market cap stands at $1.8 million.
    • Oncology Institute (NASDAQ:TOI) shares declined by 7.76% to $1.07. The market value of their outstanding shares is at $79.5 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AEON alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AEON
    $ARDX
    $ATHE
    $BFRG

    CompanyDatePrice TargetRatingAnalyst
    Ardelyx Inc.
    $ARDX
    1/9/2026Neutral → Overweight
    Piper Sandler
    Cardiff Oncology Inc.
    $CRDF
    1/5/2026$12.00Outperform
    Noble Capital Markets
    The Oncology Institute Inc.
    $TOI
    11/25/2025$5.00Buy
    Needham
    Owens & Minor Inc.
    $OMI
    11/3/2025$4.00Buy → Neutral
    UBS
    Ardelyx Inc.
    $ARDX
    9/3/2025$14.00Strong Buy
    Raymond James
    The Oncology Institute Inc.
    $TOI
    7/23/2025$8.00Outperform
    Noble Capital Markets
    The Oncology Institute Inc.
    $TOI
    7/16/2025$6.00Buy
    B. Riley Securities
    Cardiff Oncology Inc.
    $CRDF
    7/8/2025$19.00Buy
    Ladenburg Thalmann
    More analyst ratings

    $AEON
    $ARDX
    $ATHE
    $BFRG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Solana Company (NASDAQ: HSDT) Announces Plan for the Pacific Backbone, a High-Speed Infrastructure Buildout for Solana

    Deployment to be focused on Asia-Pacific region to capitalize on fast-growing wealth accumulation, cross-border payments, and institutional adoption of digital assetsExpansion planned to enable Solana Company to capture more value by eliminating external costs and providing compliant infrastructure for regulated institutionsStrategic buildout designed to address needs of market makers, high-frequency traders, exchanges, and traditional finance partners across the Solana ecosystem NEWTOWN, Pa., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Solana Company (NASDAQ:HSDT or the "Company") today rolled out a strategic roadmap to invest in a new low-latency cluster in Asia Pacific to drive staking and v

    2/23/26 9:00:00 AM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    The Oncology Institute Appoints Kim Tzoumakas to Board of Directors

    CERRITOS, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. ("TOI") (NASDAQ:TOI), one of the largest value-based oncology groups in the United States, today announced the appointment of Kim Tzoumakas to its Board of Directors, effective February 23, 2026. Ms. Tzoumakas brings more than two decades of executive leadership experience across oncology, pharmacy services and healthcare operations. Notably, she is Chief Executive Officer for VytlOne National Pharmacy Services, and previously held the CEO role at 21st Century Oncology, where she successfully led the organization through a multi-year operational turnaround, culminating in its strategic sale. She also has serve

    2/23/26 8:00:00 AM ET
    $TOI
    Medical/Nursing Services
    Health Care

    Ardelyx Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    IBSRELA revenue grew 73% in 2025 to $274.2 million and total revenues reached $407.3 million Patient-first XPHOZAH strategy preserved access and drove growth in total dispenses Development programs for new IBSRELA indication and next-generation NHE3 inhibitor launched Company is well capitalized to meet current business objectives Conference call scheduled for 4:30 PM Eastern Time WALTHAM, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today reported financial results for the fourth quarter and full year

    2/19/26 4:01:00 PM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AEON
    $ARDX
    $ATHE
    $BFRG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Ardelyx upgraded by Piper Sandler

    Piper Sandler upgraded Ardelyx from Neutral to Overweight

    1/9/26 8:23:44 AM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Noble Capital Markets initiated coverage on Cardiff Oncology with a new price target

    Noble Capital Markets initiated coverage of Cardiff Oncology with a rating of Outperform and set a new price target of $12.00

    1/5/26 9:06:54 AM ET
    $CRDF
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Needham initiated coverage on The Oncology Institute with a new price target

    Needham initiated coverage of The Oncology Institute with a rating of Buy and set a new price target of $5.00

    11/25/25 8:00:05 AM ET
    $TOI
    Medical/Nursing Services
    Health Care

    $AEON
    $ARDX
    $ATHE
    $BFRG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    PRESIDENT & CEO Bancroft Robert E. was granted 3,000,000 shares, increasing direct ownership by 1,694% to 3,177,103 units (SEC Form 4)

    4 - AEON Biopharma, Inc. (0001837607) (Issuer)

    2/19/26 8:40:27 PM ET
    $AEON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Accounting Officer Lindsay Brigitte Ute

    4 - Cardiff Oncology, Inc. (0001213037) (Issuer)

    2/18/26 4:02:04 PM ET
    $CRDF
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Interim CEO Mohindru Mani

    4 - Cardiff Oncology, Inc. (0001213037) (Issuer)

    2/18/26 4:01:02 PM ET
    $CRDF
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AEON
    $ARDX
    $ATHE
    $BFRG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Coliseum Capital Management, Llc bought $8,099,544 worth of shares (1,537,852 units at $5.27) (SEC Form 4)

    4 - OWENS & MINOR INC/VA/ (0000075252) (Issuer)

    8/14/25 8:23:48 PM ET
    $OMI
    Medical Specialities
    Health Care

    Director Pace Gary W bought $710,500 worth of shares (290,000 units at $2.45), increasing direct ownership by 26% to 1,330,676 units (SEC Form 4)

    4 - Cardiff Oncology, Inc. (0001213037) (Issuer)

    7/31/25 4:05:05 PM ET
    $CRDF
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Mott David M bought $725,880 worth of shares (200,000 units at $3.63), increasing direct ownership by 7% to 2,896,871 units (SEC Form 4)

    4 - ARDELYX, INC. (0001437402) (Issuer)

    6/18/25 9:28:07 PM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AEON
    $ARDX
    $ATHE
    $BFRG
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for XPHOZAH issued to ARDELYX INC

    Submission status for ARDELYX INC's drug XPHOZAH (ORIG-1) with active ingredient TENAPANOR has changed to 'Approval' on 10/17/2023. Application Category: NDA, Application Number: 213931, Application Classification: Type 10 - New Indication Submitted as Distinct NDA - Not Consolidated

    10/20/23 4:37:52 AM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for XPHOZAH issued to ARDELYX INC

    Submission status for ARDELYX INC's drug XPHOZAH (ORIG-1) with active ingredient TENAPANOR has changed to 'Approval' on 10/17/2023. Application Category: NDA, Application Number: 213931, Application Classification: Labeling

    10/18/23 4:43:04 PM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for XPHOZA™ issued to ARDELYX INC

    Submission status for ARDELYX INC's drug XPHOZA™ (ORIG-1) with active ingredient TENAPANOR has changed to 'Approval' on 10/17/2023. Application Category: NDA, Application Number: 213931, Application Classification: Labeling

    10/18/23 4:37:08 PM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AEON
    $ARDX
    $ATHE
    $BFRG
    SEC Filings

    View All

    Bullfrog AI Holdings Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

    8-K - BullFrog AI Holdings, Inc. (0001829247) (Filer)

    2/20/26 8:28:41 PM ET
    $BFRG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Ardelyx Inc.

    144 - ARDELYX, INC. (0001437402) (Subject)

    2/20/26 6:07:59 PM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Ardelyx Inc.

    144 - ARDELYX, INC. (0001437402) (Subject)

    2/20/26 5:33:56 PM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AEON
    $ARDX
    $ATHE
    $BFRG
    Financials

    Live finance-specific insights

    View All

    Ardelyx Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    IBSRELA revenue grew 73% in 2025 to $274.2 million and total revenues reached $407.3 million Patient-first XPHOZAH strategy preserved access and drove growth in total dispenses Development programs for new IBSRELA indication and next-generation NHE3 inhibitor launched Company is well capitalized to meet current business objectives Conference call scheduled for 4:30 PM Eastern Time WALTHAM, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today reported financial results for the fourth quarter and full year

    2/19/26 4:01:00 PM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ardelyx to Report Full Year and Fourth Quarter 2025 Financial Results on February 19, 2026

    WALTHAM, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced it will hold a conference call on Thursday, February 19, 2026, at 4:30 p.m. Eastern Time to discuss financial results and provide a business update from the full year and fourth quarter of 2025. The call will include commentary from members of the Ardelyx Executive Leadership Team including Mike Raab, President and Chief Executive Officer, Sue Hohenleitner, Chief Financial Officer, Eric Foster, Chief Commercial Officer, and Laura

    2/5/26 8:00:00 AM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cardiff Oncology Announces Positive Update from its Randomized Phase 2 Trial of Onvansertib in First-line RAS-mutated mCRC

    - Onvansertib added to FOLFIRI/bev first-line standard of care regimen showed dose-dependent improvement in overall response rates and durability trends as measured by progression-free survival in patients with RAS-mutated mCRC – - Data support selection of 30 mg onvansertib dose for registrational program in first-line RAS-mutated mCRC – - Data validate previously reported positive results from Phase 2 trial of onvansertib with FOLFIRI/bev in second-line mCRC bev-naïve patients, as published in the Journal of Clinical Oncology – - Onvansertib continues to be safe and well-tolerated – - Company expects to provide final data and registrational plans in first half of 2026 – - Company to h

    1/27/26 7:05:00 AM ET
    $CRDF
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AEON
    $ARDX
    $ATHE
    $BFRG
    Leadership Updates

    Live Leadership Updates

    View All

    The Oncology Institute Appoints Kim Tzoumakas to Board of Directors

    CERRITOS, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. ("TOI") (NASDAQ:TOI), one of the largest value-based oncology groups in the United States, today announced the appointment of Kim Tzoumakas to its Board of Directors, effective February 23, 2026. Ms. Tzoumakas brings more than two decades of executive leadership experience across oncology, pharmacy services and healthcare operations. Notably, she is Chief Executive Officer for VytlOne National Pharmacy Services, and previously held the CEO role at 21st Century Oncology, where she successfully led the organization through a multi-year operational turnaround, culminating in its strategic sale. She also has serve

    2/23/26 8:00:00 AM ET
    $TOI
    Medical/Nursing Services
    Health Care

    Alterity Therapeutics: Appendix 4C – Q2 FY26 Quarterly Cash Flow Report & Corporate Update

    − Phase 2 Data Strengthened, Strong Cash Position, and Phase 3 Planning Well Advanced − Highlights Phase 2 data for ATH434 in Multiple System Atrophy (MSA) strengthened by additional analyses and multiple international scientific presentations during the quarter.Regulatory planning activities advancing toward a pivotal Phase 3 program, including preparation for FDA End-Of-Phase-2 meeting in mid-2026.Ongoing partnering and strategic discussions with pharmaceutical companies and corporate advisers to explore non-dilutive pathways to fund Phase 3 development.Board and executive leadership strengthened to support Alterity through its next stage of clinical development, partnering and comme

    1/30/26 7:25:00 AM ET
    $ATHE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cardiff Oncology Announces Executive Leadership Changes as it Transitions to Late-Stage Clinical Development

    SAN DIEGO, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced a leadership transition designed to support the Company's next phase of growth and advancement toward late-stage development and key clinical and corporate milestones. Mani Mohindru, PhD, a member of Cardiff Oncology's Board of Directors since 2021 and a seasoned biotech executive, has been appointed interim Chief Executive Officer, effective immediately. Mark Erlander, PhD, Chief Executive Officer, and James Levine, Chief Financial Officer, have stepped down from their res

    1/27/26 7:00:00 AM ET
    $CRDF
    $CTMX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $AEON
    $ARDX
    $ATHE
    $BFRG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by NanoVibronix Inc.

    SC 13G/A - NanoVibronix, Inc. (0001326706) (Subject)

    11/14/24 5:17:34 PM ET
    $NAOV
    Industrial Specialties
    Health Care

    SEC Form SC 13G filed by AEON Biopharma Inc.

    SC 13G - AEON Biopharma, Inc. (0001837607) (Subject)

    11/14/24 5:05:14 PM ET
    $AEON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Ardelyx Inc.

    SC 13G/A - ARDELYX, INC. (0001437402) (Subject)

    11/14/24 4:08:33 PM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care